Meeting
2024 ASCO Annual Meeting
Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study.
Presenter
Min Yan, MD
Department of Breast, Henan Cancer Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Non–Subtype-Specific Breast Cancer Therapies
Clinical Trial Registration Number
NCT05357417
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 1081)
DOI
10.1200/JCO.2024.42.16_suppl.1081
Abstract #
1081
Poster Bd #
59
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2012 ASCO Annual Meeting
A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).
Speaker: Sara M. Tolaney, MD, MPH
Videos & Slides
2012 ASCO Annual Meeting
Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: Results of the first stage of a multicenter phase II study.
Speaker: Yen-Shen Lu, MD, PhD
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Results from a randomized proof-of-concept phase II trial (IMbrave151).
Speaker: Anthony B. El-Khoueiry, MD
Speaker: Panel Discussion